Siegel RL,Miller KD,Jemal A .2020 .. , 10(1) : 7-30.
. .. PMID: 31912902., : .
Idrees R,Fatima S,Abdul-Ghafar J .2018 .Cancer prevalence in Pakistan: a meta-analysis of various published studies to determine variation in cancer figures resulting from marked population heterogeneity in different parts of the country. World J Surg Oncol, 16(1) : 129-33.
. .. , : .
Goldblum JR,Lamps LW,Mckenney JK,Myers JL .2018 .Rosai and Ackerman's Surgical Pathology. , : 1066-1096.
Goldblum JR,Lamps LW,Mckenney JK,Myers JL .2018 .Rosai and Ackerman's Surgical Pathology. , : 1434-1529.
Li BT,Makker V,Buonocore DJ,Offin MD .2018 .A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J Clin Oncol, 36 : 2502-11.
Scholl S,Beuzeboc P,Pouilart P.,Targeting P. .2001 .Her-2 in other tumor types. Annals Oncol, 12 : 81-85.
Koshkin VS,O'Donnell P,Yu EY,Grivas P .2019 .. Systematic Review: Targeting HER2 in Bladder Cancer. 1 Jan, : 1-12.
Kumar S,Prajapati O,Vaiphei K,Parmar KM,Sriharsha AS,Singh SK .2015 .Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype? South Asian J Cancer. , 10(3) : PMC4756484-330X.
Sarkis J,Alkassis M,Assaf J . .Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma. Arab J Urol., : .
.2020 .. 2020 Nov, 1835439(4) : 273-274.
. .. PMID: 33425393; PMCID: PMC7755410., : .
. .Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features. 2018 Oct, 10 : PMC6190725-7185.
Mooso BA .2015 .The role of EGFR family inhibitors in muscle invasive bladder cancer: A review of clinical data and molecular evidence. J Urol, 193 : 19-29.
EK Rowinsky .2004 .The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med, 55 : 433-57.